GIPR/GLP-1R-targeting agents have demonstrated significant efficacy in appetite suppression and weight reduction; however, their adverse effect profiles and tolerability issues highlight the need for ...

Obesity and diabetes are known risk factors for sarcopenia. Insulin resistance that occurs during type 2 diabetes promotes impaired synthesis of muscle protein and muscle breakdown. Juvena ...

Previously, Juvena had received a $254,000 SBIR award from NIH for work on "biologics for improved aged muscle function," plus a $3.9 million grant from the California Institute for Regenerative ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs.

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs ...

Juvena Therapeutics, Inc. (Juvena), a platform-driven clinical-stage company unlocking the therapeutic potential of stem-cell secreted proteins and translating them into a growing pipeline of ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.

REDWOOD CITY, CA, USA I June 11, 2025 I Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, ...

Eli Lilly is partnering with privately held Juvena Therapeutics because the company has a platform that’s used for mapping stem-cell-secreted proteins that can help build and maintain muscle mass.

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research collaboration with US pharma major Eli Lilly (NYSE: LLY) to discover, develop, and ...

Juvena Therapeutics A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic muscle and metabolic diseases.

Juvena Therapeutics is a platform-driven, clinical-stage company unlocking the therapeutic potential of stem-cell secreted proteins and translating them into a growing pipeline of engineered ...